

From: Richard Abrams <richard.abrams@gmail.com>
Sent: Friday, February 05, 2010 9:29 AM
To: McDonald, William
Cc: Conrad Swartz
Subject: Re: FDA inquiry

Dear Dr. McDonald,

Dr. Swartz and I have discussed the 5 questions raised by Dr. Park and can provide the following very rough, personal estimates:

1. 1200-1500
2. We have no way of even roughly estimating this figure.
3. Essentially no other devices.
3. 0-2%
5. 0%

I'm not sure how useful any answers you obtain might be since there is simply no hard information available on any of these points.

Regards,

Dick Abrams

On Thu, Feb 4, 2010 at 6:00 PM, McDonald, William <wmcdona@emory.edu> wrote:

Dear Drs. Swartz and Abrams,

I am on the ECT Task Force for ECT and have been asked by the FDA to gather some basic information on devices. I have gotten some information from MECTA and want to also get information on the Thymatron. I wrote you a few weeks ago but perhaps you did not get the email. Here was the email I got from the FDA and I would appreciate any information you could provide. Thank you.

Bill McDonald, MD

JB Fuqua Professor of Psychiatry

Emory University

Hi Dr. McDonald,

As you know, we are working on the ECT reclassification process at FDA. In the process of analyzing the information that has come in, a few questions arose that we did not have the answer to. We were hoping that either you or someone at APA might know the answers to these questions.

1. Approximately how many sites in the US do ECT?
2. What percentage of devices are Somatics or Mecta (estimate)?
3. What other devices are being used?
3. Estimate for percentage Medcraft?
5. Estimate for percentage Elcot?

Any information you may have, even if it your personal estimate, would be greatly appreciated.

Thanks very much,

Larry Park

Lawrence Park, A.M., M.D., Medical Officer

U.S. Food and Drug Administration

Center for Devices and Radiologic Health

Division of Ophthalmic, Neurologic and ENT Devices

Office of Device Evaluation

10903 New Hampshire Avenue

WO66 - 2451

Silver Spring, MD 20993

phone: (301) 796-5620

lawrence.park@fda.hhs.gov <<mailto:lawrence.park@fda.hhs.gov>>

This e-mail message (including any attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this message (including any attachments) is strictly prohibited.

If you have received this message in error, please contact the sender by reply e-mail message and destroy all copies of the original message (including attachments).